NK cell infusion for AML patients with minimal cancer left
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with newly diagnosed or secondary AML
- Your leukemia must be in remission (morphologic CR) but with minimal residual disease (MRD-positive) after chemo
- You need a family donor whose natural killer cells are a mismatch with yours (haploidentical donor)
- You must be healthy enough for a stem cell transplant (ASCT)
- Your heart, lungs, kidneys, and liver must work well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.